|
1
|
Vincent C, Neale G and Woloshynowych M:
Adverse events in British hospitals: Preliminary retrospective
record review. BMJ. 322:517–519. 2001.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Baker GR, Norton PG, Flintoft V, Blais R,
Brown A, Cox J, Etchells E, Ghali WA, Hébert P, Majumdar SR, et al:
The Canadian adverse events study: The incidence of adverse events
among hospital patients in Canada. CMAJ. 170:1678–1686.
2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hurvitz S, Guerin A, Brammer M, Guardino
E, Zhou ZY, Latremouille Viau D, Wu EQ and Lalla D: Investigation
of adverse-event-related costs for patients with metastatic breast
cancer in a real world setting. Oncologist. 19:901–908.
2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wong W, Yim YM, Kim A, Cloutier M,
Gauthier-Loiselle M, Gagnon-Sanschagrin P and Guerin A: Assessment
of costs associated with adverse events in patients with cancer.
PLoS One. 13(e0196007)2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rashid N, Koh HA, Baca HC, Li Z, Malecha
S, Abidoye O and Masaquel A: Clinical impact of
chemotherapy-related adverse events in patients with metastatic
breast cancer in an integrated health care system. J Manag Care
Spec Pharm. 21:863–871. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Caggiano V, Weiss RV, Rickert TS and
Linde-Zwirble WT: Incidence, cost, and mortality of neutropenia
hospitalization associated with chemotherapy. Cancer.
103:1916–1924. 2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Shune SE, Karnell LH, Karnell MP, Van
Daele DJ and Funk GF: Association between severity of dysphagia and
survival in patients with head and neck cancer. Head Neck.
34:776–784. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mathijssen RH, Sparreboom A and Verweij J:
Determining the optimal dose in the development of anticancer
agents. Nat Rev Clin Oncol. 11:272–281. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ranchon F, Salles G, Späth HM, Schwiertz
V, Vantard N, Parat S, Broussais F, You B, Tartas S, Souquet PJ, et
al: Chemotherapeutic errors in hospitalised cancer patients:
Attributable damage and extra costs. BMC Cancer.
11(478)2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Phillips J, Beam S, Brinker A, Holquist C,
Honig P, Lee LY and Pamer C: Retrospective analysis of mortalities
associated with medication errors. Am J Health Syst Pharm.
58:1835–1841. 2001.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chewning B and Wiederholt JB: Concordance
in cancer medication management. Patient Educ Couns. 50:75–78.
2003.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Strasser F, Sweeney C, Willey J,
Benisch-Tolley S, Palmer JL and Bruera E: Impact of a half-day
multidisciplinary symptom control and palliative care outpatient
clinic in a comprehensive cancer center on recommendations, symptom
intensity, and patient satisfaction: A retrospective descriptive
study. J Pain Symptom Manage. 27:481–491. 2004.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Iihara H, Ishihara M, Matsuura K,
Kurahashi S, Takahashi T, Kawaguchi Y, Yoshida K and Itoh Y:
Pharmacists contribute to the improved efficiency of medical
practices in the outpatient cancer chemotherapy clinic. J Eval Clin
Pract. 18:753–760. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Shah S, Dowell J and Greene S: Evaluation
of clinical pharmacy services in a hematology/oncology outpatient
setting. Ann Pharmacother. 40:1527–1533. 2006.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Han JM, Ah YM, Suh SY, Jung SH, Hahn HJ,
Im SA and Lee JY: Clinical and economic impact of pharmacists'
intervention in a large volume chemotherapy preparation unit. Int J
Clin Pharm. 38:1124–1132. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Shah S, Dowell J and Greene S: Evaluation
of clinical pharmacy services in a hematology/oncology outpatient
setting. Ann Pharmacother. 40:1527–1533. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Suzuki H, Suzuki S, Kamata H, Sugama Y,
Demachi K, Ikegawa K, Igarashi T and Yamaguchi M: Impact of
pharmacy collaborating services in an outpatient clinic on
improving adverse drug reactions in outpatient cancer chemotherapy.
J Oncol Pharm Pract. 25:1558–1563. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Martin JK Jr and Norwood MB: Pharmacist
management of antiemetic therapy under protocol in an oncology
clinic. Am J Hosp Pharm. 45:1322–1328. 1988.PubMed/NCBI
|
|
19
|
Horne AL and Dapolite LA: Protocol for
pharmacist management of antineoplastic drug-induced adverse
effects in outpatients. Am J Health Syst Pharm. 54:680–683.
1997.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gums TH, Uribe L, Vander Weg MW, James P,
Coffey C and Carter BL: Pharmacist intervention for blood pressure
control: Medication intensification and adherence. J Am Soc
Hypertens. 9:569–578. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Borghaei H, Yim YM, Guerin A, Pivneva I,
Shi S, Gandhi M and Ionescu-Ittu R: Severe adverse events impact
overall survival and costs in elderly patients with advanced
non-small cell lung cancer on second-line therapy. Lung Cancer.
119:112–119. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rashid N, Koh HA, Baca HC, Lin KJ, Malecha
SE and Masaquel A: Economic burden related to chemotherapy-related
adverse events in patients with metastatic breast cancer in an
integrated health care system. Breast Cancer. 8:173–181.
2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Suzuki A, Kobayashi R, Okayasu S, Kuze B,
Aoki M, Mizuta K and Itoh Y: Pharmacotherapy for adverse events
reduces the length of hospital stay in patients admitted to
otolaryngology ward: A single arm intervention study. PLoS One.
9(e115879)2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hou S, Huh B, Kim HK, Kim KH and Abdi S:
Treatment of chemotherapy-induced peripheral neuropathy: Systematic
review and recommendations. Pain Physician. 21:571–592.
2018.PubMed/NCBI
|
|
25
|
Classen DC, Pestotnik SL, Evans RS, Lloyd
JF and Burke JP: Adverse drug events in hospitalized patients.
Excess length of stay, extra costs, and attributable mortality.
JAMA. 277:301–306. 1997.PubMed/NCBI
|
|
26
|
Bates DW, Spell N, Cullen DJ, Burdick E,
Laird N, Petersen LA, Small SD, Sweitzer BJ and Leape LL: The costs
of adverse drug events in hospitalized patients. JAMA. 277:307–311.
1997.PubMed/NCBI
|
|
27
|
Nishida S, Hayashi Y, Suzuki A, Kobayashi
R, Inuzuka T and Itoh Y: Relationship between number of drugs and
duration of hospital stay in older patients with neuromuscular
diseases. Geriatr Gerontol Int. 18:1018–1024. 2018.PubMed/NCBI View Article : Google Scholar
|
